title: PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.
abstract: Epidemiologic data in adult men exhibit a strong relationship between erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), indicating that men affected by ED should also be investigated for LUTS/BPH and those presenting with storage or voiding LUTS should be investigated for co-morbid ED. Common pathophysiolgical mechanisms underlying both LUTS/BPH and ED, including alteration of NO/cGMP or RhoA/Rho-kinase signaling and/or vascular or neurogenic dysfunction, are potential targets for proposed phosphodiesterase type 5 inhibitors (PDE5-Is). Several randomized controlled trials and only a few reviews including all commercially available PDE5-Is demonstrated the safety and efficacy of these drugs in the improvement of erectile function and urinary symptoms, in patients affected either by ED, LUTS, or both conditions.
authors.affiliation: Department of Urology, University of Florence, Careggi Hospital, Viale Pieraccini 18, 50139 Florence, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gacci
authors.forename: A
authors.initials: A
authors.lastname: Sebastianelli
authors.forename: M
authors.initials: M
authors.lastname: Salvi
authors.forename: L
authors.initials: L
authors.lastname: Vignozzi
authors.forename: G
authors.initials: G
authors.lastname: Corona
authors.forename: K T
authors.initials: KT
authors.lastname: McVary
authors.forename: S A
authors.initials: SA
authors.lastname: Kaplan
authors.forename: M
authors.initials: M
authors.lastname: Oelke
authors.forename: M
authors.initials: M
authors.lastname: Maggi
authors.forename: M
authors.initials: M
authors.lastname: Carini
keywords: BPH; Benign prostatic hyperplasia; ED; Erectile dysfunction; IIEF; IPSS; LUTS; Lower urinary tract symptoms; PDE5; PDE5-I; Prostate